CD44 and breast carcinoma: Our result indicating that only very few patients showed potential breast cancer stem cell markers, CD44+/CD24- (one out of 99 patients) or ALDH1 (four out of 99 patients) may be in accordance with previous studies of proof of concept on cancer stem cells.